


	CIB MTR	OMB No: 0915-0310
1. Page	Ųse Only	Expiration Date: 10/31/2022
	Sequ ence Num ber: Date Rece ived:	Public Burden Statement: The purpose of the data collection is to fulfill the legislative mandate to establish and maintain a standardized database of allogeneic marrow and cord blood transplants performed in the United States or using a donor from the United States. The data collected also meets the C.W. Bill Young Cell Transplantation Program requirements to provide relevant scientific information not containing individually identifiable information available to the public in the form of summaries and data sets. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0915-0310 and it is valid until 10/31/2022. This information collection is stem Cell Therapeutic and Research Act of 2005, Public Law (Pub. L.) 109–129, as amended by the Stem Cell Therapeutic and Research Reauthorization Act of 2015, Public Law 111–264 (the Act) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015, Public Law 114-104. Public reporting burden for this collection of information is estimated to averace 0.68 hours per response. including the time for reviewing instructions. searching existing

Center Identification	
CIBMTR Center Number:	
EBMT Code (CIC):	
Recipient Identification	
CIBMTR Research ID (CRID):	
Event date: / / /	
	_YYYYMM DD



- Western European
- □ White Caribbean
- □ White South or Central American
- Other White
- □ African
- African American
- Black Caribbean
- Black South or Central American
- Other Black
- Alaskan Native or Aleut
- North American Indian
- American Indian, South or Central America
- Caribbean Indian
- □ South Asian
- □ Filipino (Pilipino)
- □ Japanese
- □ Korean
- □ Chinese
- □ Vietnamese
- Other Southeast Asian
- Guamanian
- □ Hawaiian
- □ Samoan
- □ Other Pacific Islander
- Unknown

C	
n	
~	۰

Country of primary residence:

- 7. State of residence of recipient: (for residents of Brazil) ______ Go to question 10.
- 8. Province or territory of residence of recipient: (for residents of Canada) _____- Go to question 10.

9. State of residence of recipient: (for residents of USA)

11. Zip or postal code for place of recipient's residence (USA recipients only): ________

(last 4 digits optional)

- 12. Specify blood type: (recipient) (For allogeneic HCTs only)
 - A
 - [] В
 - 🛛 AB
 - [] O
- 13. Specify Rh factor: (recipient) (For allogeneic HCTs only)
 - Positive
 - Negative
- 14. Has the recipient signed an IRB / ethics committee (or similar body) approved consent form for submitting research data to the NMDP / CIBMTR?
 - Yes (recipient consented) Go to question 15.
 - □ No (recipient declined) *Go to question* 17.
 - □ Not approached *Go to question 17.*

15. Did the recipient give permission to be directly contacted by CIBMTR for future research?

- □ Yes (recipient provided permission) *Go to question 16.*
- □ No (recipient declined) Go to question 17.

- 17. Has the recipient signed an IRB / ethics committee (or similar body) approved consent form to donate research blood samples to the NMDP / CIBMTR?
 - □ Yes (recipient consented) *Go to question 18.*
 - No (recipient declined) Go to question 21.
 - □ Not approached Go to question 21.
 - □ Not applicable (center not participating) *Go to question 21.*

YYYY MM DD

- 19. Did the recipient submit a research sample to the NMDP/CIBMTR repository? (Related donors only)
 - □ Yes Go to question 20.
 - \square No Go to question 21.

CIBMTR Form 2400 revision 7 (page 4 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

			20.	Research sample recipient ID:
21.				? (clinical trial sponsors that use CIBMTR forms to capture outcomes data)
	_		to question 22.	
	🛛 No	– Go	to question 26.	
	22.	Stud	y Sponsor:	
			BMT CTN – Go to question 24	l.
			RCI BMT - Go to question 24	
			PIDTC - Go to question 24.	
			USIDNET – Go to question 25	
			COG – Go to question 25.	
			Other sponsor - Go to questio	n 23.
			23. question 25 .	Specify other sponsor: Go to
			24.	Study ID Number:
			25.	Subject ID:
	Сору	quest	ions 2225. to report participat	ion in more than one study.
				Hematopoietic Cellular Transplant (HCT) and Cellular Therapy
26.			quent HCT planned as part of the nt)? (For autologous HCTs only	overall treatment protocol (not as a reaction to post-HCT disease
		Yes	– Go to question 27.	
		No –	Go to question 28.	
	27.	Spec	cify subsequent HCT planned:	
			Autologous	
			Allogeneic	

- 28. Has the recipient ever had a prior HCT?
 - Yes Go to question 29.
 - □ No Go to question 40.
 - Specify the number of prior HCTs: _____ 29.

CIBMTR Form 2400 revision 7 (page 5 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

- 30. Were all prior HCTs reported to the CIBMTR?
 - Yes - Go to question 35.
 - No - Go to question 31.
 - Unknown - Go to question 31.

Copy and complete questions 31.- 34. to report all prior HCTs that have not yet been reported to the CIBMTR:

____ □ date 31. Date of the prior HCT: estimated DD YYYY MM

32. Was the prior HCT performed at a different institution?

- Yes Go to question 33.
- \square No - Go to question 34.

Specify the institution that performed the last HCT:

		33.	Name:
			City:
			State:
		Country:	
	34.		What was the HPC source for the prior HCT?
		Autologous	
		Allogeneic, unrelated	
		Allogeneic, related	
Reaso	on for c	current HCT:	
	Graft f	ailure / insufficient hemate	opoietic recovery – <i>Go to question 36.</i>

- Persistent primary disease- Go to question 40.
- Recurrent primary disease- Go to question 37.
- Planned subsequent HCT, per protocol- Go to question 40.
- New malignancy (including PTLD and EBV lymphoma) - Go to question 38.
- Insufficient chimerism- Go to question 40.
- Other- Go to question 39.

35.

CIBMTR Form 2400 revision 7 (page 6 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

36. Go to question 40.		Date of graft failure / rejection:
		YYYY MM DD
37. question 40.		Date of relapse:
4	YYYY	MM DD
38. Go to question 40.		Date of secondary malignancy:
		YYYY MM DD
39. 40.		Specify other reason: Go to question

- 40. Has the recipient ever had a prior cellular therapy? (do not include DLIs)
 - Yes Go to question 41.
 - □ No Go to question 46.

Unknown– Go to question 46.

43.

- 41. Were all prior cellular therapies reported to the CIBMTR?
 - □ Yes Go to question 46.
 - \square No Go to question 42.
 - □ Unknown– Go to question 46.

Copy and complete questions 42.-45. to report all prior cellular therapies that have not yet been reported to the CIBMTR:

- Was the cellular therapy performed at a different institution?
- □ Yes Go to question 44.
- \square No Go to question 45.

44.	Name:
City:	
State:	
Country:	

CIBMTR Form 2400 revision 7 (page 7 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

Specify the source(s) for the prior cellular therapy: (check all that apply)

- □ Autologous
- □ Allogeneic, unrelated
- □ Allogeneic, related

Donor Information

46. Multiple donors?

- Yes Go to question 47.
- No Go to question 48.
- 47. Specify number of donors: _____

To report more than one donor, copy questions 48.-83. and complete for each donor.

- 48. Specify donor:
 - □ Autologous
 - □ Allogeneic, related
 - Allogeneic, unrelated
 - 49.

Specify product type: (check all that apply)

- Bone marrow
- PBSC
- □ Single cord blood unit
- □ Other product– *Go to question 50.*
- 50. Specify other product: ____
- 51. Is the product genetically modified? *if autologous, go to question 80.*. *If allogeneic related, go to question 52.*. *If allogeneic unrelated, go to question 56.*.
 - □ Yes
 - □ No
 - 52. Specify the related donor type:
 - Syngeneic (monozygotic twin) *Go to question 57.*
 - HLA-identical sibling (may include non-monozygotic twin) Go to question 57.
 - HLA-matched other relative (does NOT include a haplo-identical donor) *Go to question* 53.
 - HLA-mismatched relative– *Go to question 53.*

CIBMTR Form 2400 revision 7 (page 8 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

57.

58.

	53.		Specify the biological relationship of the donor to the recipient:	
		Mother		
		Father		
		Child		
		Sibling		
		Fraternal twin		
		Maternal aunt		
		Maternal uncle		
		Maternal cousin		
		Paternal aunt		
		Paternal uncle		
		Paternal cousin		
		Grandparent		
		Grandchild		
		Other biological relative	– Go to question 54.	
		54. question 55.	Specify other biological relative: – C	Go to
	55.		Degree of mismatch: (related donors only)	
		HLA-mismatched 1 allel		
		HLA-mismatched ≥ 2 all	eles (does include haplo-identical donor) – Go to question 57.	
Spec	ify unre	lated donor type		
	HLA n	natched unrelated		
	HLA n	nismatched unrelated		
Did N		Ro the Match facilitate the	e procurement, collection, or transportation of the product?	
	Yes		e procurement, collection, or transportation of the product?	
	No			
Was	this dor	or used for any prior HC	Ts? (for this recipient)	
	Yes			
	No			

59.

> CIBMTR Form 2400 revision 7 (page 9 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

CIBMTR	Center N	lumber:	CIBMTR Research ID:
60.	NME	0P donor ID:	Go to question 63.
61.	Non-	NMDP unrelated donor ID: (not a	applicable for related donors)
			Go to question 63.
62.	Non-	NMDP cord blood unit ID: (incluc	le related and autologous CBUs)
			Go to question 63.
	63.		Global Registration Identifier for Donors (GRID):
			_ (optional)
		DP cord blood unit, go to ques	tion 75.
		DP donor, go to question 75.	
	Nor	n-NMDP unrelated donor, go to	question 66.
	Nor	n-NMDP cord blood unit, go to	question 64.
64.	Is the	e CBU ID also the ISBT DIN num	iber?
		Yes – Go to question 66.	
		No – Go to question 65.	
		Unknown– Go to question 66.	
		65.	Specify the ISBT DIN number:
66.	-	stry or UCB Bank ID:	If 'Other registry' go to Error: Reference source not found,
	othe	rwise go to question 68.	
		67.	Specify other Registry or UCB Bank: Go to question 68.
68.		of birth: (donor / infant)	
		Known – Go to question 69.	
		Unknown – Go to question 70	
		69.	Date of birth: (donor / infant) Go
		to question 72.	
			YYYY MM DD
		70.	Age: (donor / infant)
		□ Known – Go to questi e	on 71.
		Unknown – Go to ques	<i>tion 72.</i> CIBMTR Form 2400 revision 7 (page 10 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

Age: (donor / infant) ____ 🔲 Months (use only if less than 1 year

🛛 Years

- Sex: (donor / infant)
- □ Male

72.

□ Female

71.

old)

- 73. Specify blood type: (donor) (non-NMDP allogeneic donors only)
 - *П* А
 - 🛛 В
 - □ AB
 - □ 0
- 74. Specify Rh factor: (donor) (non-NMDP allogeneic donors only)
 - *□* Positive
 - □ Negative
- 75. Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)
 - □ Reactive
 - □ Non-reactive
 - Indeterminate
 - □ Not done
 - □ Not applicable (cord blood unit)
- 76. Has the donor signed an IRB / ethics committee (or similar body) approved consent form to donate research blood samples to the NMDP / CIBMTR? (Related donors only)
 - □ Yes (donor consented) *Go to question 77.*
 - □ No (donor declined) Go to question 80.
 - □ Not approached *Go to question 80.*
 - □ Not applicable (center not participating) *Go to question 80.*

YYYY MM DD

- 78. Did the donor submit a research sample to the NMDP/CIBMTR repository? (Related donors only)
 - Yes Go to question Error: Reference source not found

CIBMTR Form 2400 revision 7 (page 11 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

- \square No Go to question 80.
 - 79.

A series of collections should be considered a <u>single product</u> when they are all from the same donor and use the same collection method and technique (and mobilization, if applicable), even if the collections are performed on different days.

- 80. Specify number of products infused from this donor: _____
- 81. Specify the number of these products intended to achieve hematopoietic engraftment: _____

Questions 82.-83. are for autologous HCT recipients only. If other than autologous skip to question 84..

- 82. What agents were used to mobilize the autologous recipient for **this** HCT? (check all that apply)
 - □ G-CSF (filgrastim, Neupogen)
 - Pegylated G-CSF (pegfilgrastim, Neulasta)
 - Plerixafor (Mozobil)
 - □ Combined with chemotherapy
 - □ Anti-CD20 (rituximab, Rituxan)
 - □ Other agent– Go to question 83.
 - 83. Specify other agent:

To report more than one donor, copy questions 48.-83. and complete for each donor.

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning)

- 84. What scale was used to determine the recipient's functional status?
 - □ Karnofsky (recipient age \ge 16 years) Go to question 85.
 - □ Lansky (recipient age \ge 1 year and < 16 years) *Go to question 86.*

Performance score prior to the preparative regimen:

- 85. Karnofsky Scale (recipient age \geq 16 years):
 - 100 Normal; no complaints; no evidence of disease *Go to question 87.*
 - 90 Able to carry on normal activity *Go to question 87.*
 - 80 Normal activity with effort *Go to question 87*.
 - CIBMTR Form 2400 revision 7 (page 12 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

- D 70 Cares for self; unable to carry on normal activity or to do active work *Go to question 87*.
- 60 Requires occasional assistance but is able to care for most needs *Go to question 87.*
- 50 Requires considerable assistance and frequent medical care *Go to question 87.*
- Disabled; requires special care and assistance *Go to question 87.*
- 30 Severely disabled; hospitalization indicated, although death not imminent *Go to question 87.*
- 20 Very sick; hospitalization necessary Go to question 87.
- D 10 Moribund; fatal process progressing rapidly *Go to question 87.*
- 86. Lansky Scale (recipient age \geq 1 year and < 16 years):
 - □ 100 Fully active
 - 90 Minor restriction in physically strenuous play
 - 80 Restricted in strenuous play, tires more easily, otherwise active
 - D 70 Both greater restrictions of, and less time spent in, active play
 - 60 Ambulatory up to 50% of time, limited active play with assistance / supervision
 - 50 Considerable assistance required for any active play; fully able to engage in quiet play
 - 40 Able to initiate quiet activities
 - □ 30 Needs considerable assistance for quiet activity
 - 20 Limited to very passive activity initiated by others (e.g., TV)
 - □ 10 Completely disabled, not even passive play

87. Recipient CMV-antibodies (IgG or Total) :

- Reactive
- □ Non-reactive
- □ Indeterminate
- Not done

Comorbid Conditions

- 88. Is there a history of mechanical ventilation?
 - □ Yes
 - □ No
- 89. Is there a history of invasive fungal infection?
 - □ Yes
 - □ No
- 90. Glomerular filtration rate (GFR) before start of preparative regimen (pediatric only)

- □ Known- Go to question 91.
- Unknown- *Go to question 92.*
- 91. Glomerular filtration rate (GFR): ____ mL/min/1.73²
- 92. Does the recipient have known complex congenital heart disease (corrected or uncorrected)? (excluding simple ASD, VSD, or PDA repair) (pediatric only)
 - Yes
 - □ No
- 93. Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI)? Source: Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-2863.
 - □ Yes- Go to question 94.
 - □ No- Go to question 100.

Specify co-existing diseases or organ impairment (check all that apply)

- Arrhythmia Any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment
- □ Cardiac -Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test
- Cerebrovascular disease -Any history of transient ischemic attack, subarachnoid hemorrhage or cerebral thrombosis, embolism, or hemorrhage
- Diabetes -Requiring treatment with insulin or oral hypoglycemic drugs in the last 4 weeks but not diet alone
- Heart valve disease -At least a moderate to severe degree of valve stenosis or insufficiency as determined by Echo; prosthetic mitral or aortic valve; or symptomatic mitral valve prolapse
- Hepatic, mild Bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of transplant OR any history of hepatitis B or hepatitis C infection
- □ Hepatic, moderate/severe -Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal
- Infection -Includes a documented infection, fever of unknown origin, or pulmonary nodules suspicious for fungal pneumonia or a positive PPD test requiring prophylaxis against tuberculosis. Patients must have started antimicrobial treatment before Day 0 with continuation of antimicrobial treatment after Day 0
- □ Inflammatory bowel disease -Any history of Crohn's disease or ulcerative colitis requiring treatment
- Obesity -Patients older than 18 years with a body mass index (BMI) > 35 kg/m2 prior to the start of conditioning or a BMI of the 95th percentile of higher for patients aged 18 years or younger
- Peptic ulcer -Any history of peptic (gastric or duodenal) ulcer confirmed by endoscopy or radiologic diagnosis requiring treatment

- Psychiatric disturbance -Presence of any mood (e.g., depression), anxiety, or other psychiatric disorder (e.g. bipolar disorder or schizophrenia) requiring continuous treatment in the last 4 weeks
- Pulmonary, moderate -Corrected diffusion capacity of carbon monoxide and/or FEV1 of 66-80% or dyspnea on slight activity attributed to pulmonary disease at transplant
- □ Pulmonary, severe -Corrected diffusion capacity of carbon monoxide and/or FEV1 of ≤ 65% or dyspnea at rest attributed to pulmonary disease or the need for intermittent or continuous oxygen during the 4 weeks prior to transplant
- Renal, moderate / severe -Serum creatinine > 2 mg/dL or > 177 μmol/L; on dialysis during the 4 weeks prior to transplant; OR prior renal transplantation -go to question 95.
- Rheumatologic -Any history of a rheumatologic disease (e.g., systemic lupus erythematosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica, etc.) requiring treatment. (Do NOT include degenerative joint disease, osteoarthritis)
- Prior malignancy-Treated at any time point in the patient's past history, other than the primary disease for which this infusion is being performed -go to question 96.

95. regim	Was the recipient on dialysis immediately prior to start of preparative nen?
	Yes
	No
	Unknown
96.	Specify prior malignancy: (check all that apply)
	Breast cancer
	Central nervous system (CNS) malignancy (e.g., glioblastoma, astrocytoma)
	Gastrointestinal malignancy (e.g., colon, rectum, stomach, pancreas, intestine, esophageal)
	Genitourinary malignancy (e.g., kidney, bladder, ovary, testicle, genitalia, uterus, cervix, prostate)
	Leukemia (includes acute or chronic leukemia)
	Lung cancer
	Lymphoma (includes Hodgkin & non-Hodgkin lymphoma)
	MDS / MPN
	Melanoma
	Multiple myeloma / plasma cell disorder (PCD)
	Oropharyngeal cancer (e.g., tongue, buccal mucosa)
	Sarcoma
	Thyroid cancer
	Other skin malignancy (basal cell, squamous)- go to question 97.
	Other hematologic malignancy -go to question 98.

Other solid tumor, prior -go to question 99.

		97. Specify other skin malignancy: (prior)
		98. Specify other hematologic malignancy: (prior)
		99. Specify other solid tumor: (prior)
		Use results within 4 weeks prior to the start of the preparative regimen, report results from the test performed closest to the start date. Biomarkers according to the augmented HCT comorbidity index Source: Biol Blood Marrow Transplant. 2015 Aug; 21(8): 1418–1424.
100.	Serur	n ferritin: (within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)
		Known – Go to question 101.
		Unknown – Go to question 104.
	101.	ng/mL (μg/L)
	102.	Date sample collected:
		Upper limit of normal for your institution:
104.	Serur	n albumin: (within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)
		Known – Go to question 105.
		Unknown – Go to question 107.
	105.	• □ g/dL □ g/L
	106.	Date sample collected:
107.	Platel	ets: (within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)
		Known – Go to question 108.
		Unknown – Go to question 110.

108. _____ [] x 10⁹/L (x 10³/mm³) [] x 10⁶/L

> CIBMTR Form 2400 revision 7 (page 16 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

109. Were platelets transfused \leq 7 days before date of test?

- □ Yes
- □ No
- □ Unknown

110. Did the recipient have a prior solid organ transplant?

- □ Yes- Go to question 111.
- □ No- Go to question 114.
- 111. Specify organ:
 - □ Bowel
 - Heart
 - □ Kidney(s)
 - □ Liver
 - □ Lung(s)
 - Pancreas
 - □ Other organ- *Go to question 112.*

112.

Specify other organ:

113. Year of prior solid organ transplant:

YYYY

Copy and complete questions 111.-113. for each prior solid organ transplant

Pre-HCT Preparative Regimen (Conditioning)

114. Height at initiation of pre-HCT preparative regimen: _____ [] inches

centimeters

115. Actual weight at initiation of pre-HCT preparative regimen: _____ . ___] pounds

🛛 kilograms

- 116. Was a pre-HCT preparative regimen prescribed?
 - □ Yes Go to question 117.
 - □ No Go to question 138.

CIBMTR Form 2400 revision 7 (page 17 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022 117. Classify the recipient's prescribed preparative regimen: (Allogeneic HCTs only)

- □ Myeloablative
- □ Non-myeloablative (NST)
- □ Reduced intensity (RIC)

118. Was irradiation planned as part of the pre-HCT preparative regimen?

- □ Yes Go to question 119.
- \square No Go to question 124.
 - 119.

What was the prescribed radiation field?

- □ Total body *Go to question 120.*
- Total body by intensity-modulated radiation therapy (IMRT) Go to question Error: Reference source not found
- □ Total lymphoid or nodal regions *Go to question 120.*
- Thoracoabdominal region *Go to question 120.*

120.] Gy	Total prescribed dose: (dose per fraction x total number of fractions)	
	🗌 cGy	
121. уууу	Date started:	
122.	Was the radiation fractionated?	
□ Yes – Go to question :	123.	

□ No – Go to question 124.

123. Total number of fractions: _____

Indicate the total prescribed cumulative dose for the preparative regimen:

124. Drug: (drop down list)

- □ Bendamustine
- □ Busulfan
- □ Carboplatin
- □ Carmustine (BCNU)
- CCNU (Lomustine)
- □ Clofarabine (Clolar)
- Cyclophosphamide (Cytoxan)

CIBMTR Form 2400 revision 7 (page 18 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

- □ Cytarabine (Ara-C)
- Etoposide (VP-16, VePesid)
- □ Fludarabine
- □ Gemcitabine
- □ Ibritumomab tiuxetan (Zevalin)
- □ Ifosfamide
- Melphalan (L-Pam)
- □ Methylprednisolone (Solu-Medrol)
- Pentostatin
- □ Propylene glycol-free melphalan (Evomela)
- Rituximab (Rituxan)
- □ Thiotepa
- □ Tositumomab (Bexxar)
- □ Treosulfan
- Other drug -go to question 125.

125. Specify other drug: ____

126. Total prescribed dose: _____. __ mg/m²

- 🗆 mg/kg
- □ AUC (mg x h/L)
- □ AUC (µmol x min/L)
- □CSS (ng/mL)

- 128. Specify administration: (busulfan only)
 - D Oral
 - D IV
 - □ Both

Copy and complete question 124.-128. to report each drug given for the preparative regimen

Additional Drugs Given in the Peri-Transplant Period

129. ALG, ALS, ATG, ATS

□ Yes – **Go to question 130**.

CIBMTR Form 2400 revision 7 (page 19 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

		No – Go to question 133.			
	130.	Total prescribed dose:	mg/kg		
	131.	Specify source:			
	□ ATGAM (horse) – <i>Go to question 133.</i>				
		□ ATG – Fresenius (rabbit) – Go to question 133.			
		Thymoglobulin (rabbit) – <i>Go to question 133.</i>			
		Other – Go to question 1	32.		
		132.	Specify other source:		
133.	Alem	ntuzumab (Campath)			
		Yes – Go to question			
		No – Go to question 135.			
	134.		Total prescribed dose:	🗆 mg/m2	
			□ mg/kg		
			□mg		
	135.		Defibrotide		
		Yes			
		No			
	136.		KGF		
		Yes			
		No			
	137.		Ursodiol		
		Yes			
		No			

GVHD Prophylaxis

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 141..

CIBMTR Form 2400 revision 7 (page 20 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

- 138. Was **GVHD** prophylaxis planned?
 - Yes Go to question 139.
 - □ No Go to question 141.
 - 139. Specify drugs / intervention: (check all that apply)
 - □ Abatacept
 - Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
 - Bortezomib
 - □ CD34 enriched (CD34+ selection)
 - □ Corticosteroids (systemic)
 - □ Cyclophosphamide (Cytoxan)
 - Cyclosporine (CSA, Neoral, Sandimmune)
 - □ Extra-corporeal photopheresis (ECP)
 - □ Ex-vivo T-cell depletion
 - □ Filgotinib
 - □ Maraviroc
 - □ Methotrexate (MTX) (Amethopterin)
 - □ Mycophenolate mofetil (MMF) (CellCept)
 - Ruxolotinib
 - □ Sirolimus (Rapamycin, Rapamune)
 - □ Tacrolimus (FK 506)
 - □ Tocilizumab
 - Blinded randomized trial
 - □ Other agent-*go to question 140.*

Specify other agent: _____ (do not report ATG, campath)

Post-HCT Disease Therapy Planned as of Day 0

- 141. Is additional post-HCT therapy planned?
 - Yes Go to question 142.
 - No Go to First Name

Questions 142.-143. are optional for non-U.S. centers

- 142. Specify post-HCT therapy planned: (check all that apply)
 - Azacytidine (Vidaza)

CIBMTR Form 2400 revision 7 (page 21 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022

- □ Blinatumomab
- □ Bortezomib (Velcade)
- Bosutinib
- Brentuximab
- Carfilzomib
- Cellular therapy (e.g. DCI, DLI)
- □ Crenolanib
- Daratumumab
- Dasatinib
- Decitabine
- Elotuzumab
- □ Enasidenib
- Gilteritinib
- □ Ibrutinib
- □ Imatinib mesylate (Gleevec, Glivec)
- □ Intrathecal therapy (chemotherapy)
- Ivosidenib
- Ixazomib
- □ Lenalidomide (Revlimid)
- □ Lestaurtinib
- □ Local radiotherapy
- □ Midostaurin
- □ Nilotinib
- □ Obinutuzumab
- □ Pacritinib
- D Ponatinib
- □ Quizartinib
- Rituximab (Rituxan, MabThera)
- □ Sorafenib
- □ Sunitinib
- □ Thalidomide (Thalomid)
- □ Other therapy- *Go to question 143.*
- □ Unknown

Specify other therapy: _____

CIBMTR Form 2400 revision 7 (page 22 of 23) Draft 1/15/2020 OMB No: 0915-0310 Expiration Date: 10/31/2022 Prior Exposure: Potential Study Eligibility

Selecting any option(s) below may generate an additional supplemental form.

144. Speci	fy if the recipient received any of the following (at any time prior to HCT / infusion) (check all that apply)			
	Blinatumomab (Blincyto)			
	Gemtuzumab ozogamicin (Mylotarg)			
	Inotuzumab ozogamicin (Besponsa)			
	Adienne Tepadina®			
	Mogamulizumab (Poteligeo)			
	None of the above			
First Name:				
Last Name [.]				
E-mail address:				
	YYYY MM DD			